Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.

The observation that approximately 70% of HIV-infected pregnant women do not transmit infection vertically suggests that antibody therapy may be effective in the prevention of transmission of HIV infection from mother to child. Currently, there is an incomplete understanding of the processes involved in vertical transmission of HIV infection. The elucidation of the serological basis of maternal immunity as it relates to protection from vertical transmission is the goal of this study. We have screened 20 maternal sera from HIV+ individuals of known vertical transmission status for reactivity with 31 peptides spanning the entire envelope glycoprotein of HIV-1. Of interest was reactivity to regions outside of the V3 loop of gp120. The findings have been examined in relationship to transmission status, as well as to in vitro anti-HIV-1 biological activity. Our results indicate that lack of vertical transmission is correlated with high viral neutralization activity, but not with antisyncytial activity nor with binding to the V3 peptides examined in this study. Also, the transmission group bound to fewer gp41 peptides when compared with the nontransmission group, suggesting that immune responses to gp41 may be important in preventing transmission. These findings may provide insights into the design of passive immunotherapies.

[1]  A. Rubinstein,et al.  Erratum: Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain (Proc. Natl. Acad. Sci. USA (May 1990) 87 (3445-3449)) , 1991 .

[2]  A. Rubinstein,et al.  Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Nelson,et al.  HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses , 1990, The Lancet.

[4]  R. M. Hendry,et al.  Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. , 1990, AIDS research and human retroviruses.

[5]  I Quinti,et al.  Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. , 1990, The Journal of infectious diseases.

[6]  J. Goedert,et al.  MOTHER-TO-INFANT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1: ASSOCIATION WITH PREMATURITY OR LOW ANTI-gp120 , 1989, The Lancet.

[7]  C. Giaquinto,et al.  Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Wahrén,et al.  Diagnostic implication of specific immunoglobulin G patterns of children born to HIV‐infected mothers , 1989, AIDS.

[9]  P. Molinoff,et al.  Subtype‐Selective Immunoprecipitation of the β2‐Adrenergic Receptor , 1989 .

[10]  D. Bolognesi.  HIV antibodies and vaccine design , 1989, AIDS.

[11]  V. De Gruttola,et al.  Incubation periods for paediatric AIDS patients , 1988, Nature.

[12]  H. Guy,et al.  Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Pizzo,et al.  Acquired immune deficiency syndrome in children. Current problems and therapeutic considerations. , 1988, American Journal of Medicine.

[14]  W. Koff,et al.  Development and testing of AIDS vaccines. , 1988, Science.

[15]  A. Dalgleish,et al.  Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. , 1988, Virology.

[16]  R. M. Hendry,et al.  Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. , 1988, The Journal of infectious diseases.

[17]  R. Weiss,et al.  Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.

[18]  R. Tedder,et al.  HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN TWO COHORTS OF HOMOSEXUAL MEN: NEUTRALISING SERA AND ASSOCIATION OF ANTI-GAG ANTIBODY WITH PROGNOSIS , 1987, The Lancet.

[19]  Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. , 1987, MMWR. Morbidity and mortality weekly report.

[20]  U. Bienzle,et al.  Neutralizing antibodies and the course of HIV-induced disease. , 1987, AIDS research and human retroviruses.

[21]  G. Linette,et al.  Induction of anti‐HIV neutralizing antibodies by synthetic peptides. , 1986, The EMBO journal.

[22]  M. Degueldre,et al.  VERTICAL TRANSMISSION OF HIV IN 15-WEEK FETUS , 1986, The Lancet.

[23]  D. Barnes.  Grim projections for AIDS epidemic. , 1986, Science.

[24]  L. Chieco‐Bianchi,et al.  Lav/HTLV-III Neutralizing Antibodies in the Sera of Patients with Aids, Lymphadenopathy Syndrome and Asymptomatic Seropositive Individuals , 1986, Tumori.

[25]  M. A. Koch,et al.  LAV/HTLV-III IN 20-WEEK FETUS , 1985, The Lancet.

[26]  J. Gold,et al.  POSTNATAL TRANSMISSION OF AIDS-ASSOCIATED RETROVIRUS FROM MOTHER TO INFANT , 1985, The Lancet.

[27]  A. Fauci,et al.  Immunologic abnormalities in the acquired immunodeficiency syndrome. , 1985, Annual review of immunology.

[28]  A. Ammann,et al.  Maternal transmission of acquired immune deficiency syndrome. , 1984, Pediatrics.

[29]  J Leibowitch,et al.  Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). , 1983, Science.

[30]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[31]  E. Engvall,et al.  Enzyme immunoassay ELISA and EMIT. , 1980, Methods in enzymology.

[32]  S. Pierce,et al.  Allogeneic carrier-specific enhancement of hapten-specific secondary B- cell responses , 1976, The Journal of experimental medicine.